Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study on the Safety and Efficacy of YTS109 Cell in Subjects With Relapsing/Refractory Autoimmune Diseases

NCT07236801 is registered in ClinicalTrials.gov with China Immunotech (Beijing) Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07236801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07236801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study on the Safety and Efficacy of YTS109 Cell in Subjects With Relapsing/Refractory Autoimmune Diseases
Lead sponsor
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
November 13, 2025
Completion date
November 13, 2027
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, inflammatory myopathy, sjogren's syndrome (ss), systemic lupus erythematosus (sle), systemic sclerosis